Figure 1. Micrographs of spinal cord motoneurons showing SOD1-immunoreactive inclusions.
Image credit: Forsberg, et. al. 2010 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email [email protected]. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! Betty Laidlaw MND Research Prize
Sponsor: MND Australia
Description: The Betty Laidlaw MND Research Prize aims to reward an outstanding mid-career researcher with a demonstrated background of excellence in neuroscience research in Australia. The Prize is for an innovative 2-year project to advance the understanding of classical MND with a clear potential for effective treatments. The award is up to $250,000 AUD over two years.
Deadline: Application due by August 30, 2019.



NEW! Innovator Grants
Sponsor: MND Australia
Description: These grants fund research in Australia  that is innovative and has a clear relationship to the causes, treatments or cures of MND or the support of people living with MND. The award is up to $100,000 AUD for one year.
Deadline: Application due by August 30, 2019.



NEW! Lasker Clinical Research Scholars
Sponsor: Lasker Foundation and NIH
Description:

The National Institutes of Health in partnership with the Lasker Foundation, is pleased to announce the Lasker Clinical Research Scholars Program, an historic “intramural-extramural” partnership to nurture the next generation of clinical researchers. The program supports a small number of exceptional clinical researchers in the early stages of their careers to promote their development to fully independent positions.


Deadline: Application due by August 30, 2019.



NEW! MDA Venture Philanthropy Program
Sponsor: Muscular Dystrophy Association
Description: MDA’s MVP program is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. The diseases funded include ALS. MVP funds projects from proof-of-principle studies through phase 2 trials. The maximum award is  $1M USD for preclinical studies, $3M USD for early clinical studies and $500,000 USD for R&D.
Deadline: Letter of Intent due by September 1, 2019.



NEW! Centres of Excellence in Neurodegeneration 2019
Sponsor: ANR, CIHR, DZNE, ISCIII, MDS, MRC
Description: The overall aim of the initiative is to build collaborative research activity in neurodegeneration research across borders, focusing on adding value to the expertise and critical mass already established within national centres of excellence (CoE), in order to accelerate progress in understanding the mechanisms of disease as well as the identification of new therapeutic approaches. This call sets out to encourage the community to think “outside the box”, to stimulate new and unconventional approaches and creative solutions to the challenges of neurodegeneration research by undertaking high-risk/high-payoff research. Target diseases include motor neuron diseases. Eligibility: Canada, France, Germany, Italy, Spain and the UK.
Deadline: Application due by November 4, 2019.



Rare As One Network
Sponsor: Chan Zuckerberg Initiative
Description: The Chan Zuckerberg Initiative is inviting patient-led 501(c)(3) organizations focused on a rare disease to apply for a two-year funding opportunity to develop and launch collaborative research networks in partnership with clinicians and researchers.
Deadline: Letter of Intent due by July 23, 2019.



Essential Open Source Software for Science
Sponsor: Chan Zuckerberg Initiative
Description: The Chan Zuckerberg Initiative invites applications for open source software projects that are essential to biomedical research. Applicants can request funding between $50k and $250k for one year. CZI will invite applications during three distinct cycles, with rounds beginning June 18, 2019.
Deadline: Letter of Intent due by August 1, 2019.



Canada-UK Artificial Intelligence Initiative
Sponsor: UKRI, CIHR, NSERC, SSHRC
Description: The rapid development and ever-growing global investment in artificial intelligence illustrate the undeniable impact that these technologies are having, and will have, on our economies, health and societies. Given the expertise of researchers in Canada and the United Kingdom, the three Canadian federal agencies and UK Research and Innovation are jointly supporting the development of a collaboration in AI between stakeholders in Canada and the UK.
Deadline: Letter of Intent due by August 19, 2019.



Clinical Trials on a Chip to Inform Clinical Trial Design and Implementation in Precision Medicine
Sponsor: National Center for Advancing Translational Sciences
Description: This FOA invites applications for projects designed to test the effectiveness of microphysiological systems, also called “tissue chip,” technology, for clinical trial frameworks by demonstrating their applied use in clinical trial planning and execution, addressing both safety and efficacy in late-stage preclinical studies. This approach is to provide evidence of the utility of tissue chip technology for precision medicine in informing trial design, establishing recruitment criteria and stratification of patient populations in identifying the best responders to candidate therapeutics.
Deadline: Letter of Intent due by September 9, 2019.



Starting Grants in ALS Basic Research
Sponsor: Bruno and Ilse Frick Foundation for Research on ALS
Description: This aim of this award is to support early-career ALS scientists by providing funding for their basic research. Scientists across the globe are encouraged to apply! The funding is 100,000 CHF over 2 years.
Deadline: Application due by September 30, 2019.



Biomedical Research Project Grants
Sponsor: Motor Neurone Disease Association
Description: The MND Association supports biomedical research on ALS and related conditions, in all relevant disciplines. The objectives of the MND Association research funding programme are to support research aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. Applications will begin to be accepted on September 6, 2019. Researchers outside the UK are eligible to apply if the project is unique in concept or design (i.e. not being performed in the UK) or the project involves a significant collaboration with a UK institute.
Deadline: Application due by October 25, 2019.



Methods to Improve Reproducibility of Human iPSC Derivation, Growth and Differentiation
Sponsor: National Center for Advancing Translational Sciences (
Description: This funding opportunity will support the development of novel, reliable and cost-effective methods to standardize and increase the utility and reproducibility of iPSCs at all stages, from their derivation to their research and clinical applications.
Deadline: Application due by January 6, 2020.



CLIN 1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion an IND or IDE filing with the FDA and initiate clinical trial start-up with a promising stem or progenitor cell-based treatment that addresses an unmet medical need. The maximum award is $6M USD. CIRM expects projects under this program to advance rapidly into the clinic and to achieve the proposed IND filing within 18 months.
Deadline: Applications due by 2PM PST on the last business day of each month.



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion of a clinical trial for a promising stem or progenitor cell-based treatment that addresses an unmet medical need. The maximum award is $10-15M USD.
Deadline: Applications due by 2PM PST on the last business day of each month.



CLIN 3: Partnering Opportunity for Stem Cell Therapy Registration Clinical Trials
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded clinical trial projects that will directly enable product registration with the Food and Drug Administration (FDA). This award is only available to holders of a current CLIN2 award for a trial that has been deemed by FDA to be sufficient for registration.
Deadline: Applications due by 2PM PST on the the last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clinical Neuroscience Research Grants
Sponsor: Dana Foundation
Description: This grant funds "first-in-man" clinical studies of therapies being developed for brain diseases. Funded studies can receive up to $300,000 payable over three years. Potential applicants may submit a preliminary proposal and budget to determine full proposal eligibility. Applications are not solely restricted to clinical research scientists based in the United States.
Deadline: Applications are accepted on a rolling basis.



Early Phase Clinical Trials, Canada (Includes FTD)
Sponsor: Weston Brain Institute
Description: The Early Phase Clinical Trials Canada program provides funding to support clinical trials and/or clinical trial sub-studies that could accelerate the development of therapeutics for neurodegenerative disease aging, including FTD. Eligible principal investigators must be at or above the level of Assistant Professor or equivalent, and be affiliated with a CRA-qualified institution located in Canada. A maximum of $1,500,000 per project over up to 4 years.
Deadline: Applications are accepted on a rolling basis.



NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis.



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Applications are accepted on a rolling basis.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail